# Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis

> **NCT01382654** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 131 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** epinastine 0.1%
- **DRUG:** epinastine 0.1% with taste masking agent
- **DRUG:** epinastine 0.2%
- **DRUG:** epinastine 0.2% with taste masking agent
- **DRUG:** azelastine 0.1%

## Key facts

- **NCT ID:** NCT01382654
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2015-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01382654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01382654, "Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01382654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*